Metamoodics includes a comprehensive meta-analysis of published candidate gene association studies of BP. Data on 33 polymorphisms in 18 genes reported on by three or more case-control studies were included in the meta-analysis. 8 A similar meta-analysis for MD is forthcoming. Schematic diagram showing in Figure 1 illustrates various resources and applications of Metamoodics.
Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis Brain-derived neurotrophic factor (BDNF) is a dimeric protein that has a central role in neurogenesis and neuroplasticity. This neurotrophin is found throughout the brain and is particularly abundant in the hippocampus and cerebral cortex, brain areas critical for the control of mood, emotion and cognition. 1 The secretion and uptake of BDNF in neurons occur at both axons and dendrites, either constitutively or in response to neural activity, and it is also synthesized and released by astrocytes.
2 It appears to be involved in the pathophysiology of mood disorders (MD) and schizophrenia (SZ), evidenced by reports of decreased serum and cerebrospinal fluid (CSF) levels in SZ, bipolar disorder (BD) and major depressive disorder (MDD). [3] [4] [5] Furthermore, BDNF levels are influenced by psychiatric medications such as antidepressants, mood stabilizers and antipsychotics. [3] [4] [5] On these grounds, BDNF levels as measured in serum and plasma have been promoted as a potential biomarker of diagnosis in these psychiatric disorders. 6 BDNF crosses the blood-brain barrier, and its levels in serum and plasma are highly correlated with BDNF levels in CSF (r = 0.8). 7, 8 Several studies have taken advantage of this 'window to the brain', with the great majority showing decreased BDNF levels in acutely ill subjects. However, the specificity, extent and relationship of peripheral BDNF levels to disease activity are not fully known; clarifying these issues was the aim of this metaanalysis. The hypothesis of this comparative meta-analysis was that peripheral BDNF levels would be lower in SZ and MD during acute episodes, and that serum or plasma BDNF could serve as a biomarker of disease activity, whereas not as a biomarker for diagnosis in these conditions.
To quantify and validate the specificity of serum and plasma BDNF levels in this study, we combined and compared results from a systematic and quantitative meta-analysis of electronic databases for MD and SZ. Inclusion criteria were studies that measured BDNF in plasma or serum in vivo in adult subjects with BD, MDD or SZ. Results from these studies were compiled to measure the effect size (ES) of BDNF level differences between patients and controls. To adjust for systematic measurement effects, we calculated the ES of each study according to Hedges' g from their means and s.d., which produces an unbiased ES adjusted for sample size. The direction of the ES was positive if patients showed increased BDNF, and negative if they showed decreased BDNF levels when compared with controls. As the data were highly skewed, we used non-parametric methods. KruskalWallis test and Conover-Inman post hoc test were used for statistical analysis. All tests were two-tailed, and we considered statistically significant P-values o 0.05. Results are shown as median and interquartile range of the ES. Studies with negative results are less likely to be published than studies with positive results. We took this into account in our statistical analyses and, although we found some evidence for publication bias, it was insufficient to affect our main results (Supplementary Material).
Our comparative meta-analysis included 99 studies involving 907 subjects with BD, 3762 with MDD, 2436 with SZ and 8795 healthy controls. Of those, 45 studies included only subjects free of use of psychiatric medication for at least 7 days (Supplementary Material). Serum and plasma BDNF levels reached highly negative ES in BD during depressive episodes (−0.98, −1.91 to − 0.50), in BD during manic episodes (−0.78, −0.99 to − 0.20), in MDD in acute episodes (−0.84, −1.32 to − 0.30) and in SZ (−0.70, −1.30 to − 0.21). There were no differences in the decreased peripheral BDNF levels among the groups (P = 0.49). As hypothesized, the ESs in BD during euthymia and in MDD in remission were near zero (−0.02, −0.25 to 0.64 and −0.07, −0.38 to 0.31, respectively, P = 0.84), suggesting no difference or small difference in BDNF levels between euthymic subjects with BD, with remitted MDD, and healthy controls. The decrease in BDNF levels was more marked in the subjects with SZ and MD in acute episodes when compared with subjects with BD in euthymia and with MDD in remission (−0.70, −1.30 to − 0.21, −0.82, −1.23 to − 0.23, and −0.02, −0.30 to 0.35, respectively, P = 0.0001). Notwithstanding the differences in peripheral BDNF levels among groups were significant, the values presented a large amplitude with noteworthy overlap, not allowing us to properly discriminate subjects in acute psychiatric states from those on remission solely on its levels ( Figure 1 ).
The present data do not allow us to distinguish whether peripheral sources produce or release less BDNF or if decreased brain protein's synthesis or release is responsible for lower plasma and serum levels. Concentrations of BDNF are much higher in serum (41000 × ) or plasma (~10 × ) than in CSF. 8 Therefore, it appears likely that blood BDNF is lower in acute episodes of MD and in SZ because of reduced peripheral than reduced cerebral synthesis/release. Much BDNF is derived from other tissues than the brain, including smooth muscle, liver and endothelial cells. However, it may still have important effects on brain and mediate the effects for instance of exercise on mood. 4, 9 Nonetheless, for a better understanding of the underlying dynamic processes, future studies should determine the ratios of BDNF concentrations in CSF in serum and plasma in both patients (acutely ill and remitted) and controls. Changes in BDNF may represent a counter-regulatory response to other etiological factors of the illness, such as metabolic and redox factors. 10 Our results support the hypothesis that BDNF is involved in the pathophysiology of both MD and SZ. These findings are in line with previous studies showing that alterations of BDNF expression are a mechanism shared by BD, MDD and SZ.
3-6 BDNF does not appear to be a diagnostic biomarker across the schizoaffective spectrum of psychiatric disorders, but may reflect underlying disease activity. However, notably, the severity of depressive symptoms in MDD seems to be unrelated to BDNF serum levels. 4 Furthermore, decreased BDNF levels may be related to the suppressive effects elicited by stress of an acute psychiatric disease episode. 9, 10 Stress may also have an important causal role in the initiation or exacerbation of psychiatric disorders that can be detected by peripheral biomarkers. Although as a trait marker, BDNF might not properly differentiate SZ, BD and MDD, it differentiates euthymia from mania and bipolar depression in BD, and the remitted from the acute state in MDD, suggesting that BDNF levels assessed peripherally in serum or plasma are a state biomarker of disease activity reflecting common pathophysiology. Yet a biomarker of disease activity, due to the large amplitude variation in BDNF serum and plasma values, it is unlikely that it will translate as an useful biomarker in clinical practice.
'The search strategy for the systematic review, study selection, data extraction and data synthesis, tables and flow diagram are described in the Supplementary Information, available on the Molecular Psychiatry website. Figure 1 . Box-plots of the effect sizes (ES) of serum and plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenia (SZ), bipolar disorder (BD) in acute mania, depression and euthymia, and major depressive disorder (MDD) in acute episode and remission from individual studies as identified by the systematic review and meta-analysis. (a) There were no differences in BDNF levels among SZ, BD in acute episodes and MDD in acute episode (Kruskal-Wallis test, P = 0.49). The decrease in BDNF levels was more marked in subjects with SZ or BD and MDD during acute episodes when compared with subjects with BD in euthymia and MDD in remission (Kruskal-Wallis test with Conover-Inman post test; P = 0.0001). (b) BDNF levels according to disease activity. Decreased BDNF levels were observed in subjects with SZ, BD and MDD during acute episodes when compared with subjects with BD in euthymia and with MDD in remission (Kruskal-Wallis test with Conover-Inman post hoc test; P = 0.0001). A total of 99 studies were included, comprising 907 subjects with BD, 3762 subjects with MDD, 2436 subjects with SZ and 8795 controls (21, 31 and 54 studies, respectively; some studies contributed to more than one diagnostic group). The presence of statistical significance is identified by the letters a and b. Identical letters denote absence of significance, and different letters denote presence of significance.
